Insider Selling: Axon Enterprise (NASDAQ:AXON) President Sells $9,636,063.25 in Stock

Axon Enterprise, Inc (NASDAQ:AXON) President Joshua Isner sold 16,775 shares of Axon Enterprise stock in a transaction on Monday, August 31st. The shares were sold at an average price of $574.43, for a total value of $9,636,063.25. Following the completion of the transaction, the president owned 296,974 shares in the company, valued at $170,590,774.82. This represents a 5.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Joshua Isner also recently made the following trade(s):

• On Friday, June 5th, Joshua Isner sold 13,000 shares of Axon Enterprise stock. The shares were sold at an average price of $488.45, for a total value of $6,349,850.00.

Axon Enterprise Stock Performance

Shares of AXON stock opened at $515.67 on Friday. The business has a fifty day moving average of $569.47 and a 200 day moving average of $486.24. The firm has a market capitalization of $41.89 billion, a price-to-earnings ratio of 213.97, a price-to-earnings-growth ratio of 8.74 and a beta of 1.40. Axon Enterprise, Inc has a 1 year low of $339.01 and a 1 year high of $792.16. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.15 and a quick ratio of 1.80.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported $1.88 EPS for the quarter, beating the consensus estimate of $1.84 by $0.04. Axon Enterprise had a net margin of 6.19% and a return on equity of 2.84%. The company had revenue of $904.39 million for the quarter, compared to analyst estimates of $876.42 million. During the same period in the prior year, the company earned $2.12 earnings per share. The firm’s revenue was up 35.3% on a year-over-year basis. As a group, research analysts expect that Axon Enterprise, Inc will post 2.04 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Argus boosted their price target on shares of Axon Enterprise from $460.00 to $600.00 and gave the stock a “buy” rating in a report on Thursday. Piper Sandler raised their price objective on shares of Axon Enterprise from $724.00 to $732.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. UBS Group increased their price objective on Axon Enterprise from $440.00 to $600.00 and gave the stock a “neutral” rating in a research report on Thursday, August 6th. The Goldman Sachs Group restated a “buy” rating and issued a $715.00 target price on shares of Axon Enterprise in a research report on Thursday, August 6th. Finally, Morgan Stanley increased their price target on Axon Enterprise from $600.00 to $640.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Fourteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, Axon Enterprise has an average rating of “Moderate Buy” and a consensus target price of $721.57.

Institutional Investors Weigh In On Axon Enterprise

Several large investors have recently bought and sold shares of AXON. Rockefeller Capital Management L.P. boosted its position in shares of Axon Enterprise by 53.2% during the 4th quarter. Rockefeller Capital Management L.P. now owns 11,518 shares of the biotechnology company’s stock worth $6,542,000 after acquiring an additional 4,002 shares in the last quarter. Legal & General Group Plc increased its stake in Axon Enterprise by 1.3% in the fourth quarter. Legal & General Group Plc now owns 426,533 shares of the biotechnology company’s stock valued at $242,241,000 after purchasing an additional 5,419 shares during the last quarter. Eurizon Capital SGR S.p.A. acquired a new stake in Axon Enterprise during the fourth quarter worth approximately $13,116,000. B. Metzler seel. Sohn & Co. AG purchased a new stake in shares of Axon Enterprise during the 2nd quarter worth approximately $3,854,000. Finally, Arrowstreet Capital Limited Partnership acquired a new position in shares of Axon Enterprise in the 1st quarter valued at $15,067,000. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.